Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
28 hedge funds and large institutions have $6.12M invested in Aevi Genomic Medicine Inc in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 2 closing their positions.
646% more capital invested
Capital invested by funds: $820K → $6.12M (+$5.3M)
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
12% more funds holding
Funds holding: 25 → 28 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$30.5K |
| 2 |
JC
JBF Capital
Aspen,
Colorado
|
+$25.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$17.6K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$14.6K |
| 5 |
VF
Virtu Financial
New York
|
+$11.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$65.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$24K |
| 3 |
BC
Birchview Capital
Burlington,
Vermont
|
-$19K |
| 4 |
Barclays
London,
United Kingdom
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$68 | +500 | New |
|
GNMX Hedge Fund Activity: Q4 2019 in Review
28 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2019, worth a combined $6.12M — up 646% from $820K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GNMX positions and 2 closed out — a net gain of 3 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $30.5K. The largest seller was Vanguard Group, cutting an estimated $65.8K.
- 28 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2019, up from 25 in Q3 2019.
- Funds reported $6.12M of Aevi Genomic Medicine Inc stock for Q4 2019, up 646% quarter-over-quarter.
- 5 funds opened new Aevi Genomic Medicine Inc positions in Q4 2019 and 2 closed out, a net change of +3 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q4 2019 was Renaissance Technologies, an estimated $30.5K added.
- The largest Aevi Genomic Medicine Inc seller in Q4 2019 was Vanguard Group, an estimated $65.8K sold.
Based on aggregated 13F filings for Q4 2019.